Second-generation antipsychotic use in borderline personality disorder: What are we targeting?

INTRODUCTION: Borderline personality disorder (BPD) is a personality disorder plagued with high rates of psychotropic polypharmacy. Estimates show that second-generation antipsychotics (SGAs) are used in most of these patients; however, they are being prescribed off label. METHODS: A literature revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasylyshen, Adrian, Williams, Andrew M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2016
Materias:
Personality Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007581/
https://www.ncbi.nlm.nih.gov/pubmed/29955452
http://dx.doi.org/10.9740/mhc.2016.03.82
Descripción
Sumario:INTRODUCTION: Borderline personality disorder (BPD) is a personality disorder plagued with high rates of psychotropic polypharmacy. Estimates show that second-generation antipsychotics (SGAs) are used in most of these patients; however, they are being prescribed off label. METHODS: A literature review was conducted via PubMed in search for studies evaluating SGA use in BPD. RESULTS: There are available data investigating 8 of 11 SGAs and their use in BPD. Of N = 269 potential articles, N = 34 evaluating the use of SGAs in BPD were included. DISCUSSION: Strong evidence supporting SGAs in BPD is lacking. Potential target symptoms in which a SGA may be useful include depression, anxiety, anger, impulsivity, and paranoia/dissociative behavior.

Ejemplares similares